Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2004-07-09
2008-05-06
Campell, Bruce H. (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S185100, C424S204100
Reexamination Certificate
active
07368537
ABSTRACT:
The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response.
REFERENCES:
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 5716637 (1998-02-01), Anselem et al.
patent: 5726292 (1998-03-01), Lowell
patent: 5848152 (1998-12-01), Slipy et al.
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6476201 (2002-11-01), Lowell et al.
patent: 6699478 (2004-03-01), Hancock et al.
patent: 2001/0053368 (2001-12-01), Burt et al.
patent: 2003/0044425 (2003-03-01), Burt et al.
patent: 2004/0197348 (2004-10-01), Hancock et al.
patent: WO 99/14334 (1999-03-01), None
patent: WO 01/60402 (2001-08-01), None
patent: WO 02/058725 (2002-08-01), None
Murphy et al. Virus Research 1994 vol. 32, pp. 13-36.
Mader et al. Vaccine 2000 vol. 18, pp. 1110-1117.
Huang et al. Vaccine vol. 21, pp. 2500-2505, 2003.
Beasley, R. et al., “Viral respiratory tract infection and exacerbations of asthma in adult patients,”Thorax, 43(9):679-683, Sep. 1988.
Connors, M. et al., “Enhanced Pulmonary Histopathology Induced by Respiratory Syncytial Virus (RSV) Challenge of Formalin-Inactivated RSV-Immunized BALB/c Mice Is Abrogated by Depletion of Interleukin-4 (IL-4) and IL-10,”Journal of Virology, 68(8):5321-5325, Aug. 1994.
Doherty, P.C., “Vaccines and cytokine-mediated pathology in RSV infection,”Trends Microbiol., 2:148, 1994.
Glezen, W.P. et al., “Risk of Primary Infection and Reinfection With Respiratory Syncytial Virus,”American Journal of Diseases of Children, 140(6):543-546, Jun. 1986.
Glezen, W.P. et al., “Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level,”The Journal of Pediatrics, 98(5):708-715, May 1981.
Graham, B.S. et al., “Priming Immunization Determines T Helper Cytokine mRNA Expression Patterns in Lungs of Mice Challenged with Respiratory Syncytial Virus,”The Journal of Immunology, 151(4):2032-2040, Aug. 15, 1993.
Grünig, G. et al., “Requirement for IL-13 Independently of IL-4 in Experimental Asthma,”Science, 282(5397):2261-2263, Dec. 18, 1998.
Hemming, V.G. et al., “Hyperimmune Globulins in Prevention and Treatment of Respiratory Syncytial Virus Infections,”Clinical Microbiology Reviews, 8(1):22-33, Jan. 1995.
Holberg, C.J. et al., “Risk Factors for Respiratory Syncytial Virus-associated Lower Respiratory Illnesses in the First Year of Life,”American Journal of Epidemiology, 133(11):1135-1151, Jun. 1, 1991.
Huang, Y. and Anderson, R., “A single amino acid substitution in a recombinant G protein vaccine drastically curtails protective immunity against respiratory syncytial virus (RSV),”Vaccine, 21:2500-2505, 2003.
Huang, Y. and Anderson, R., “Enhanced immune protection by a liposome-encapsulated recombinant respiratory syncytial virus (RSV) vaccine using immunogenic lipids fromDeinococcus radiodurans,” Vaccine, 20:1586-1592, 2002.
Hussell, T. and Openshaw, P.J.M., “Intracellular IFN-γ expression in natural killer cells precedes lung CD8+T cell recruitment during respiratory syncytial virus infection,”Journal of General Virology, 79:2593-2601, 1998.
Johnson, T.R. and Graham, B.S., “Secreted Respiratory Syncytial Virus G Glycoprotein Induces Interleukin-5 (IL-5), IL-13, and Eosinophilia by an IL-4-Independent Mechanism,”Journal of Virology, 73(10):8485-8495, Oct. 1999.
Kakuk, T.J. et al., “A Human Respiratory Syncytial Virus (RSV) Primate Model of Enhanced Pulmonary Pathology Induced with a Formalin-Inactivated RSV Vaccine but Not a Recombinant FB Subunit Vaccine,”The Journal of Infectious Diseases, 167(3):553-561, Mar. 1993.
Kirby, C. and Gregoriadis, G., “Dehydration-Rehydration Vesicles: A Simple Method for High Yield Drug Entrapment in Liposomes,”Bio/Technology, 2:979-984, Nov. 1984.
Lamprecht, C.L. et al., “Role of Maternal Antibody in Pneumonia and Bronchiolitis Due to Respiratory Syncytial Virus,”The Journal of Infectious Diseases, 134(3):211-217, Sep. 1976.
Levine, S. et al., “Demonstration that Glycoprotein G Is the Attachment Protein of Respiratory Syncytial Virus,”The Journal of General Virology, 68:2521-2524, 1987.
Lowell, G.H. et al., “Peptides Bound to Proteosomes via Hydrophobic Feet Become Highly Immunogenic Without Adjuvants,”The Journal of Experimental Medicine, 167(2):658-663, Feb. 1, 1988.
Lowell, G.H. et al., “Proteosome-Lipopeptide Vaccines: Enhancement of Immunogenicity for Malaria CS Peptides,”Science, 240:800-802, 1988.
Lowell, G., “Proteosomes for Improved Nasal, Oral, or Injectable Vaccines,”New Generation Vaccines, 2ndEdition, Marcel Dekker, Inc. USA, 193-206, 1997.
Lynch, E.C. et al., “Spontaneously Transferred from Whole Cells and Reconstituted from Purified Proteins ofNeisseria gonorrhoeaeandNeisseria meningitidis,”Biophysical Journal, 45(1):104-107, Jan. 1984.
Murphy, B.R. et al., “Dissociation between Serum Neutralizing and Glycoprotein Antibody Responses of Infants and Children Who Received Inactivated Respiratory Syncytial Virus Vaccine,”Journal of Clinical Microbiology, 24(2):197-202, Aug. 1986.
Murphy, B.R. et al., “An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines,”Virus Research, 32(1):13-36, 1994.
Navas, L. et al., “Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children,”The Journal of Pediatrics, 121(3):348-354, Sep. 1992.
Openshaw, P.J.M. and O'Donnell, D.R., “Asthma and the common cold: can viruses imitate worms?”Thorax, 49:101-103, 1994.
Openshaw, P.J.M. et al., “Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface of glycoprotein G,”International Immunology, 4(4):493-500, 1992.
Ryan, E.J. et al., “Immunomodulators and delivery systems for vaccination by mucosal routes,”TRENDS in Biotechnology, 19(8):293-304, Aug. 2001.
Sparer, T.E. et al., “Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia,”Journal of Experimental Medicine, 187(11):1921-1926, Jun. 1, 1998.
Spender, L.C. et al., “Abundant IFN-γ production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease,”Journal of General Virology, 79:1751-1758, 1998.
Srikiatkhachorn, A. et al., “Induction of Th-1 and Th-2 Responses by Respiratory Syncytial Virus Attachment Glycoprotein Is Epitope and Major Histocompatibility Complex Independent,”Journal of Virology, 73(8):6590-6597, Aug. 1999.
Srikiatkhachorn, A. and Braciale, T.J., “Virus-Specific Memory and Effector T Lymphocytes Exhibit Different Cytokine Responses to Antigens during Experimental Murine Respiratory Syncytial Virus Infection,”Journal of Virology, 71(1):678-685, Jan. 1997.
Tebbey, P.W. et al., “Atypical Pulmonary Eosinophilia Is Mediated by a Specific Amino Acid Sequence of the Attachment (G) Protein of Respiratory Syncytial Virus,”Journal of Experimental Medicine, 188(10):1967-1972, Nov. 16, 1998.
Trinchieri, G., “Biology of Natural Killer Cells,”Advances in Immunology, 47:187-376, 1989.
Varga, S.M. et al., “The Attachment (G) Glycoprotein of Respiratory Syncytial Virus Contains a Single Immunodominant Epitope That Elicits Both Th1 and Th2 CD4+T Cell Responses,”The Journal of Immunology, 165:6487-6495, 2000.
Anderson Robert
Burt David S.
Huang Yan
Campell Bruce H.
Gimmi Edward R.
Hecht Elizabeth J.
Hill Myron G.
ID Biomedical Corporation of Quebec
LandOfFree
Subunit vaccine against respiratory syncytial virus infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Subunit vaccine against respiratory syncytial virus infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Subunit vaccine against respiratory syncytial virus infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3983073